Moderna, Inc. (MRNA) reported earnings of $3.07 per share in the first quarter of 2024, beating the Zacks Consensus Estimate of a loss of $3.59. In the year-ago period, management posted earnings of 19 cents per share. This bottom-line downtick was due to lower product sales during the quarter.Revenues in the quarter were $167 million, beating the Zacks Consensus Estimate of $124.7 million. Total revenues declined 91% year over year due to reduced COVID-19 vaccine sales during the quarter.Shares of Moderna ...

Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Lavina Talukdar - SVP & Head of IR Stéphane Bancel - CEO Stephen Hoge - President Jamey Mock - CFO Conference Call Participants Salveen Richter - Goldman Sachs Michael Yee - Jefferies Terence Flynn - Morgan Stanley Eliana Merle - UBS Hartaj Singh - Oppenheimer Gena Wang - Barclays Luca Issi - RBC Capital Jessica Fye - J.P. Morgan Unidentified Analyst - Evan Wang - Guggenheim Securities Simon Baker - Red ...

Forward-looking statements and disclaimer 2 Financials Jamey Mock, CFO usiness Revie | --- | --- | --- | --- | --- | --- | |--------------------------|-------|-------|-------|-------|-------| | | | | | | | | vaccines | | | | | | | addressing | | | | | | | respiratory and | | | | | | | latent + other pathogens | | | | | | | | | | | | | © 2024 Moderna, Inc. All rights reserved. Financial figures in this presentation as of, and for the quarterly periods ended, March 31, 2024, and March 31, 2023, are unaudited. ...

The biotech sector includes companies that utilize biological processes to develop technologies and products for a wide range of industries. This includes healthcare, agriculture, and environmental management. These companies often focus on innovative therapies, medical diagnostics, and genetic research. Biotech stocks are known for their high growth potential. This is primarily due to the revolutionary nature of their products and the increasing demand for advanced medical treatments.Investing in biotech s ...

Moderna (MRNA) came out with a quarterly loss of $3.07 per share versus the Zacks Consensus Estimate of a loss of $3.59. This compares to earnings of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.48%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.78 per share when it actually produced earnings of $0.55, delivering a surprise of 170.51%.Over the last four quarters, the company ...

Moderna Inc (NASDAQ: MRNA) reported a narrower-than-expected loss for the first quarter of the year, setting a positive tone as it prepares to launch its second product in the U.S. market later this year.Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.Moderna beats loss estimates, revenue expectationsCopy link to sectionIn the first quarter, Moderna recorded a net loss of $1.175 billion, or $3.07 per share, which was less than the anticipated loss of ...

Moderna on Thursday posted a narrower-than-expected loss for the first quarter as the company's cost-cutting efforts took hold and sales of its Covid vaccine, its only commercially available product, topped estimates. The results come as Moderna inches closer to putting another product on the market, which it badly needs as demand for Covid shots plunges worldwide. The biotech company expects a U.S. approval for its vaccine against respiratory syncytial virus on May 12. If cleared, that shot is expected to ...

Exhibit 99.1 Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07) Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billion Initiated three new clinical studies evaluating Moderna’s investigational individualized neoantigen therapy in combination with Merck’s Keytruda® for treatment of patient ...

USA News Group Commentary Issued on behalf of BioVaxys Technology Corp. VANCOUVER, BC, May 1, 2024 /PRNewswire/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of cancer. A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%. According to experts at last year's annual American Society of Clinical Oncology (ASCO) meeting, a little-kno ...

Moderna (MRNA) will report first-quarter 2024 results on May 2, before the opening bell. In the last reported quarter, the company reported an earnings surprise of 170.51%.Factors to NoteThe Zacks Consensus Estimate for Moderna’s total revenues is pegged at around $125 million, while the same for earnings stands at a loss of $3.59 per share. Both metrics indicate significant declines from the year-ago quarter’s levels.During the first quarter, sales of COVID-19 vaccines are likely to have declined due to lo ...